A forty-fold spending increase, a billion-dollar fraud sentence, a rate cut that kills a business model on contact, and a Christmas Eve reversal that nobody saw coming. How Medicare collapsed a ten-billion-dollar market in ninety days — without ever touching the coverage rules.
Under the pre-2026 payment structure, Medicare reimbursed most skin substitutes under the ASP+6% methodology used for biologicals. The design was coherent for drugs with competitive markets and disciplined launch prices. It was not coherent for a product category where manufacturers could set launch prices above $2,000 per square centimeter, collect ASP+6% on every application, and pay clinicians "spread" arrangements that functioned as kickbacks by any honest reading.
The incentive ran one direction. Higher list price meant higher reimbursement meant higher clinician margin meant higher volume. A 2023 OIG investigation found that nearly half of the relevant billing codes lacked required ASP pricing submissions, leaving CMS to rely on inflated benchmarks. The system had no brake.
By 2024, Medicare was spending over $10 billion annually on skin substitutes — more than 15% of all Part B drug spending — while beneficiary volume had only doubled. The delta was pricing and overutilization, not patient need.
The 2025 National Health Care Fraud Takedown charged 324 defendants across 50 federal districts. Wound care was not a footnote. It was headline copy. What follows is a partial roster.
Medicare payments for amniotic wound allografts have exploded, driven by illegal kickbacks from wholesalers and medically unnecessary applications by providers incentivized by high reimbursement rates.
— DOJ Criminal Fraud Section, 2025 Year in Review (Jan. 22, 2026)The October 31 final rule reclassified most skin substitutes from biologicals to "incident-to supplies" and set a uniform payment rate across physician office and hospital outpatient settings. The CAA of 2021 had already required ASP submissions; the new rule stopped pretending those submissions would discipline pricing.
Products licensed under PHSA §351 remain on ASP methodology. Everything else falls under the flat rate. Reimbursement is now tied strictly to applied surface area — no payment for discarded or unused material. Measurement precision, previously a clinical formality, is now the audit vector.
The withdrawn LCDs would have accomplished by coverage restriction what the PFS accomplished by payment math. With the rate cut live, the products that depended on inflated ASP for viability exit the market regardless of whether they remain "covered." This is the tell.
AATB and manufacturers are lobbying for rate increases. APMA formally opposed the payment proposal but won on arthrodesis RVUs — CPT 28755 jumped from 4.88 to 7.50 wRVU — as partial consolation. The trade association response continues, but the economics are settled for CY 2026.
Three MACs — Novitas, CGS, and First Coast — kept their own skin substitute policies active. Providers in those jurisdictions are not on the same glide path as the rest of the country.